An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

• Status: Terminated
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the efficacy, safety and tolerability of a new formulation of glatiramer acetate administered at 20 mg/0.5 ml daily versus placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Pharmaceutical Industries
• Treatments: (T,G)-A-L; Glatiramer Acetate

Criteria

Inclusion Criteria:

Subjects must meet all inclusion criteria in order to be eligible for the study:

• Subjects must have a confirmed and documented multiple sclerosis (MS) diagnosis as defined by the 2010 Revised McDonald criteria [Ann Neurol 2011: 69:292-302], with a relapsing-remitting disease course.

• Subjects must be ambulatory with a Kurtzke's Expanded Disability Status Scale (EDSS) score of 0-5.5 in both screening and baseline visits.

• Subjects must be in a relapse-free, stable neurological condition and free of corticosteroid treatment [intravenous (IV), intramuscular (IM) and/or by mouth (PO)] or ACTH (adrenocorticotropic hormone) 30 days prior to screening (Month-1) and between screening and baseline (Month 0) visits.

• Subjects must have experienced one of the following:

• At least one documented relapse in the 12 months prior to screening,

• At least two documented relapses in the 24 months prior to screening,

• One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in a magnetic resonance imaging (MRI) performed within 12 months prior to screening.

• Subjects must be between 18 and 55 years of age, inclusive.

• Women of child-bearing potential must practice an acceptable method of birth control [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or a double-barrier method (condom or diaphragm with spermicide)].

• Subjects must be able to sign and date a written informed consent prior to entering the study.

• Subjects must be willing and able to comply with the protocol requirements for the duration of the study.

Exclusion Criteria:

Any of the following conditions will exclude the subject from entering the study:

• Subjects with progressive forms of MS.

• Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.

• Use of immunosuppressive agents (including Mitoxantrone and Fingolimod) or cytotoxic agents within 6 months prior to the screening visit.

• Use of natalizumab (Tysabri®) or any other monoclonal antibodies within 2 years prior to screening.

• Use of cladribine within 2 years prior to screening.

• Previous treatment with immunomodulators [including IFNβ 1a and 1b, and IV Immunoglobulin (IVIg)] within 2 months prior to screening.

• Previous use of glatiramer acetate (GA) or any other glatiramoid.

• Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.

• Previous total body irradiation or total lymphoid irradiation.

• Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.

• Pregnancy or breastfeeding.

• Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG, abnormal laboratory tests and chest X-ray. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment.

• A known history of sensitivity to Gadolinium.

• Glomerular filtration rate (GFR) ≤ 60 mL/minute at the screening visit

• Inability to successfully undergo MRI scanning.

• A known drug hypersensitivity to Mannitol.

• Subjects who underwent endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI).